BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23462194)

  • 21. Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment.
    Feng F; Wang H; Fu H; Wu S; Ye Z; Chen S; Li J
    Nucl Med Biol; 2011 Oct; 38(7):1053-8. PubMed ID: 21982575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of melatonin on the toxicity and proliferation of human anaplastic thyroid cancer cell line.
    Ghorbani-Anarkooli M; Dabirian S; Zendedel A; Moladoust H; Bahadori MH
    Acta Histochem; 2021 Apr; 123(3):151700. PubMed ID: 33667778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lentiviral-mediated transfection of hTSHR in poorly differentiated thyroid carcinoma cell line.
    Cheng W; Fu H; Feng F; Ma C; Li J; Chen S; Wang H
    Nucl Med Biol; 2013 May; 40(4):576-80. PubMed ID: 23618770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
    Hecht M; Erber S; Harrer T; Klinker H; Roth T; Parsch H; Fiebig N; Fietkau R; Distel LV
    PLoS One; 2015; 10(6):e0130277. PubMed ID: 26086472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
    D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
    J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.
    Feng F; Wang H; Hou S; Fu H
    Nucl Med Biol; 2012 Nov; 39(8):1261-5. PubMed ID: 22898315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
    Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
    Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
    Lavarone E; Puppin C; Passon N; Filetti S; Russo D; Damante G
    Mol Cell Endocrinol; 2013 Jan; 365(1):1-10. PubMed ID: 22982218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.
    Lee YJ; Chung JK; Shin JH; Kang JH; Jeong JM; Lee DS; Lee MC
    Thyroid; 2004 Nov; 14(11):889-95. PubMed ID: 15671766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
    Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
    J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.